Article Details
Retrieved on: 2024-03-05 14:23:05
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Tonix Pharmaceuticals has recently reported encouraging findings on TNX-1500, a cutting-edge third-generation anti-CD40L monoclonal antibody (mAb) ...
Article found on: beststocks.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here